SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake
Am J Physiol Renal Physiol. 2024 Apr 25. doi: 10.1152/ajprenal.00005.2024. Online ahead of print.ABSTRACTBeyond glycemic control, SGLT2 inhibitors (SGLT2i) have protective effects on cardiorenal function. Renoprotection has been suggested to involve inhibition of NHE3 leading to reduced ATP-dependent tubular workload and mitochondrial oxygen consumption. NHE3 activity is also important for regulation of endosomal pH, but the effects of SGLT2i on endocytosis are unknown. We used a highly differentiated cell culture model of proximal tubule (PT) cells to determine the direct effects of SGLT2i on Na+-dependent fluid transport...
Source: Am J Physiol Renal P... - April 25, 2024 Category: Urology & Nephrology Authors: Wafaa N Albalawy Elynna B Youm Katherine E Shipman Keelan J Trull Catherine J Baty Kimberly R Long Youssef Rbaibi Xue-Ping Wang Olayemi G Fagunloye Katharine A White Michael J Jurczak Ossama B Kashlan Ora A Weisz Source Type: research
Statement of Retraction: Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome
Volume 40, Issue 1, December 2024 . (Source: Gynecological Endocrinology)
Source: Gynecological Endocrinology - April 25, 2024 Category: Endocrinology Source Type: research
Vitamin B12 deficiency in diabetic patients treated with metformin: A cross-sectional study
This study set out to evaluate the rate of vitamin B12 deficiency in Vietnamese patients with type 2 diabetes who were t reated with metformin and to investigate factors associated with vitamin B12 deficiency. This is a cross-sectional study that was conducted in Vinmec Central Park Hospital from February to June 2023. The clinical and paraclinical characteristics of the participants were recorded, and the levels of v itamin B12 and folate were measured. The rate of vitamin B12 deficiency in patients treated with metformin was found to be 18.6%. Further, the duration of diabetes, duration of metformin use, metformin dose, ...
Source: PLoS One - April 25, 2024 Category: Biomedical Science Authors: Dat Tan Huynh Source Type: research
Metformin modulates autophagic pathway in renal fibrosis induced by carbon tetrachloride in adult male albino rats
CONCLUSION: Metformin administration can modulate histological and biochemical effects in the renal tissue induced by of ccl4.PMID:38654519 | DOI:10.1080/01913123.2024.2342444 (Source: Ultrastructural Pathology)
Source: Ultrastructural Pathology - April 24, 2024 Category: Pathology Authors: Amal T Abou-Elghait Rania M Al Adly Eman Radwan Fatma Y Meligy Source Type: research
The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial —Study Design and Protocol
AbstractIntroductionMultiple daily injection insulin regimen (MDI) represents the most intensive insulin regimen used in the management of people with type 2 diabetes (PwT2D). Its efficacy regarding glycaemic control is counterbalanced by the increased risk of hypoglycaemia, frequently observed tendency to weight gain and necessity for frequent glucose monitoring. Recent introduction of novel antidiabetic medications with pleiotropic effects reaching far beyond the reduction of glycaemia (HbA1c), such as the glucagon-like peptide 1 receptor agonist (GLP-1 RA), has significantly widened the therapeutic options available for...
Source: Diabetes Therapy - April 24, 2024 Category: Endocrinology Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Dipeptidyl peptidase 4 inhibitors vs. metformin for new-onset dementia: a propensity score-matched cohort study
CONCLUSION: In this real-world study, we found that DPP4 inhibitors presented an association with a lower risk of dementia in individuals with type 2 diabetes than metformin, particularly in older people and those without diabetes-related comorbidities.PMID:38652239 | DOI:10.1210/clinem/dgae281 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 23, 2024 Category: Endocrinology Authors: Siyang Liu Heng Wan Sheng Nie Huanyi Cao Lan Liu Hua Liang Hong Xu Bicheng Liu Chunbo Chen Huafeng Liu Qiongqiong Yang Hua Li Yaozhong Kong Guisen Li Qijun Wan Yan Zha Ying Hu Gang Xu Yongjun Shi Yilun Zhou Guobin Su Ying Tang Mengchun Gong Aixin Guo Jian Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Dipeptidyl peptidase 4 inhibitors vs. metformin for new-onset dementia: a propensity score-matched cohort study
CONCLUSION: In this real-world study, we found that DPP4 inhibitors presented an association with a lower risk of dementia in individuals with type 2 diabetes than metformin, particularly in older people and those without diabetes-related comorbidities.PMID:38652239 | DOI:10.1210/clinem/dgae281 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 23, 2024 Category: Endocrinology Authors: Siyang Liu Heng Wan Sheng Nie Huanyi Cao Lan Liu Hua Liang Hong Xu Bicheng Liu Chunbo Chen Huafeng Liu Qiongqiong Yang Hua Li Yaozhong Kong Guisen Li Qijun Wan Yan Zha Ying Hu Gang Xu Yongjun Shi Yilun Zhou Guobin Su Ying Tang Mengchun Gong Aixin Guo Jian Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
An in vitro study of metformin adsorption to activated charcoal
. (Source: Clinical Toxicology)
Source: Clinical Toxicology - April 22, 2024 Category: Toxicology Authors: Yoshinori TomodaMasahiro KobayashiLaboratory of Clinical Pharmacokinetics, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, Tokyo, Japan Source Type: research
Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects
Neurobiol Dis. 2024 Apr 18:106505. doi: 10.1016/j.nbd.2024.106505. Online ahead of print.ABSTRACTAlzheimer's and Parkinson's diseases are two of the most frequent neurological diseases. The clinical features of AD are memory decline and cognitive dysfunction, while PD mainly manifests as motor dysfunction such as limb tremors, muscle rigidity abnormalities, and slow gait. Abnormalities in cholesterol, sphingolipid, and glycerophospholipid metabolism have been demonstrated to directly exacerbate the progression of AD by stimulating Aβ deposition and tau protein tangles. Indirectly, abnormal lipids can increase the burden o...
Source: Neurobiology of Disease - April 20, 2024 Category: Neurology Authors: Bin Tong Yaoqi Ba Zhengyang Li Caidi Yang Kangtai Su Haodong Qi Deju Zhang Xiao Liu Yuting Wu Yixuan Chen Jitao Ling Jing Zhang Peng Yu Xiaoping Yin Source Type: research
Miniature mass spectrometer-based point-of-care assay for quantification of metformin and sitagliptin in human blood and urine
This study developed a point-of-care (POC) assay method utilizing a miniature mass spectrometer, enabling rapid and accurate quantification of MET and STG concentrations in human blood and urine. By combining the miniature mass spectrometer with paper spray ionization, this method simplifies the process into three to four steps, requires minimal amounts of bodily fluids (50 μL of blood and 2 μL of urine), and is able to obtain quantification results within approximately 2 min. Stable isotope-labeled internal standards were employed to enhance the accuracy and stability of measurement. The MS/MS responses exhibited good l...
Source: Analytical and Bioanalytical Chemistry - April 20, 2024 Category: Chemistry Authors: Jingying Chen Yaohan Li Jingjing Chen Ruimin Wang Miaoshan Lu Changbin Yu Source Type: research
Effect of metformin in hypothalamic astrocytes from an immunocompromised mice model
Biochimie. 2024 Apr 18:S0300-9084(24)00080-4. doi: 10.1016/j.biochi.2024.04.005. Online ahead of print.ABSTRACTAstrocytes are glial cells that play key roles in neuroinflammation, which is a common feature in diabetic encephalopathy and aging process. Metformin is an antidiabetic compound that shows neuroprotective properties, including in inflammatory models, but astroglial signaling pathways involved are still poorly known. Interferons α/β are cytokines that participate in antiviral responses and the lack of their signaling increases susceptible to viral infections. Here, we investigated the effects of metformin on ast...
Source: Biochimie - April 20, 2024 Category: Biochemistry Authors: Larissa Daniele Bobermin Daniele Schauren da Costa Aline Daniel Moreira de Moraes Vanessa Fernanda da Silva Giancarlo Tomazzoni de Oliveira Patr ícia Sesterheim Ana Carolina Tramontina Luiz Augusto Basso Guilhian Leipnitz Andr é Quincozes-Santos Carlos- Source Type: research
